Seventh Statin Appoved: Kowa Will Take A Niche Strategy For Livalo
This article was originally published in PharmAsia News
Executive Summary
Kowa's decision to emphasize its newly approved statin Livalo'seffect in populations that are hard to treat with other statins is a wise strategy for a late entry to a class dominated by popular generics and well-established brands from marketing powerhouses like Pfizer and AstraZeneca